Travere Historical Income Statement
| TVTX Stock | USD 18.18 0.07 0.38% |
Historical analysis of Travere Therapeutics income statement accounts such as Total Other Income Expense Net of 665.7 K, Income Tax Expense of 234.2 K, Depreciation And Amortization of 19.6 M or Research Development of 123.1 M can show how well Travere Therapeutics performed in making a profits. Evaluating Travere Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Travere Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Travere Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Travere Therapeutics is a good buy for the upcoming year.
Travere |
About Travere Income Statement Analysis
Travere Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Travere Therapeutics shareholders. The income statement also shows Travere investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Travere Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Travere Therapeutics. It is also known as Travere Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Travere Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Travere Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Travere Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Travere Stock please use our How to Invest in Travere Therapeutics guide.At this time, Travere Therapeutics' Interest Income is fairly stable compared to the past year.
| 2021 | 2022 | 2023 | 2024 (projected) | Research Development | 210.3M | 235.8M | 245.0M | 123.1M | Depreciation And Amortization | 26.6M | 20.7M | 38.5M | 19.6M |
Travere Therapeutics income statement Correlations
Click cells to compare fundamentals
Travere Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Travere Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 18.8M | 19.1M | 20.1M | 11.3M | 11.3M | 16.4M | |
| Selling General Administrative | 129.0M | 135.8M | 149.9M | 220.2M | 265.5M | 278.8M | |
| Other Operating Expenses | 275.1M | 273.7M | 367.0M | 463.6M | 522.0M | 548.1M | |
| Operating Income | (99.8M) | (75.4M) | (139.5M) | (251.6M) | (376.7M) | (357.9M) | |
| Ebit | (99.8M) | (169.7M) | (213.3M) | (320.1M) | (364.8M) | (346.5M) | |
| Ebitda | (69.7M) | (144.0M) | (186.7M) | (299.4M) | (326.2M) | (309.9M) | |
| Total Operating Expenses | 269.9M | 267.6M | 360.2M | 456.0M | 472.0M | 495.6M | |
| Income Before Tax | (146.4M) | (188.8M) | (179.7M) | (278.2M) | (376.1M) | (357.3M) | |
| Total Other Income Expense Net | (46.6M) | (113.4M) | 19.7M | (11.3M) | 634K | 665.7K | |
| Net Income | (146.4M) | (169.4M) | (180.1M) | (278.5M) | (111.4M) | (117.0M) | |
| Income Tax Expense | (21K) | (19.4M) | 409K | 313K | 223K | 234.2K | |
| Depreciation And Amortization | 30.1M | 25.8M | 26.6M | 20.7M | 38.5M | 19.6M | |
| Research Development | 141.0M | 131.8M | 210.3M | 235.8M | 245.0M | 123.1M | |
| Total Revenue | 175.3M | 198.3M | 227.5M | 212.0M | 145.2M | 169.3M | |
| Gross Profit | 170.1M | 192.2M | 220.7M | 204.4M | 133.8M | 163.4M | |
| Cost Of Revenue | 5.2M | 6.1M | 6.8M | 7.6M | 11.5M | 5.9M | |
| Tax Provision | (21K) | (19.4M) | 409K | 313K | 223K | 234.2K | |
| Net Interest Income | (8.8M) | (14.0M) | (18.1M) | (5.0M) | 10.4M | 11.0M | |
| Net Income From Continuing Ops | (146.4M) | (169.4M) | (180.1M) | (278.5M) | (376.3M) | (357.5M) | |
| Reconciled Depreciation | 20.4M | 24.6M | 26.6M | 33.1M | 38.5M | 28.2M | |
| Net Income Applicable To Common Shares | (146.4M) | (169.4M) | (180.1M) | (278.5M) | (250.6M) | (238.1M) | |
| Interest Income | 10.1M | 5.0M | 2.0M | 6.3M | 21.8M | 22.9M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.